Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
0.00%
)
Bitcoin
68,694.01
(
-0.28%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 213943

Monday, 10/30/2017 10:15:23 AM

Monday, October 30, 2017 10:15:23 AM

Post# of 257269
NVS acquires AAAP for $82/ADS—a 44% premium to AAAP’s Nasdaq closing price on 9/27/17 (the day before it was reported that NVS might buying the company):

https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-advanced-accelerator-applications

AAAP has an approved radiotherapy called Lutathera for rare GI and pancreatic cancers.

The nominal deal value is $3.9B. NVS plans to initiate a tender offer and will complete the buyout if ≥80% of AAAP shares are tendered.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today